AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19282417 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy home exercise program
Number of subjects: 44
Study 19282417 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) with stimulation
Number of subjects: 44
Study 18067679 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with sulphadoxine‐pyrimethamine (SP)
Number of subjects: 1070
Study 15504852 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 14 assessment
Number of subjects: 13772
Study 15504852 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 28 assessment
Number of subjects: 13772
Study 15504852 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall failure rate
Number of subjects: 13772
Study 11449082 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined oral HRT (2 mg of estradiol plus 1 mg of norethisterone acetate)
Number of subjects: 22
Study 11449082 — intervention group
Group type: COMPARATOR
Intervention: No treatment (controls)
Number of subjects: 22
Study 9740348 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-monitored outpatient-care programme
Number of subjects: 158
Study 9740348 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (usual care)
Number of subjects: 158
Study 8113061 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH third-grade classroom curriculum
Number of subjects: 0
Study 2844680 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 52
Study 2844680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 29980396 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurable left ventricles
Number of subjects: 522
Study 29980396 — intervention group
Group type: COMPARATOR
Intervention: No left ventricles
Number of subjects: 522
Study 28025442 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Matricaria chamomilla L. mouthwash
Number of subjects: 30
Study 28025442 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine (CHX)
Number of subjects: 30
Study 28025442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25668505 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical β-glucan
Number of subjects: 356
Study 25668505 — intervention group
Group type: COMPARATOR
Intervention: Control (follow-up only)
Number of subjects: 356
Study 24119081 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced postoperative care with frequent follow‐up by a care navigator (10 calls over 6 months)
Number of subjects: 0
Study 24119081 — intervention group
Group type: COMPARATOR
Intervention: Usual postoperative care (no navigator phone calls)
Number of subjects: 0
Study 21907115 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular distance visual acuity
Number of subjects: 129
Study 21907115 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular near visual acuity
Number of subjects: 129
Study 21907115 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of distance and near visual acuity
Number of subjects: 129
Study 21907115 — intervention group
Group type: COMPARATOR
Intervention: Distance visual acuity
Number of subjects: 129
Study 21907115 — intervention group
Group type: COMPARATOR
Intervention: Near visual acuity
Number of subjects: 129
Study 21907115 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity difference analysis
Number of subjects: 129
Study 18289829 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic Online (PO), an internet‐based CBT intervention (n=46)
Number of subjects: 86
Study 18289829 — intervention group
Group type: COMPARATOR
Intervention: Best practice face‐to‐face CBT (n=40)
Number of subjects: 86
Study 17050891 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 531 (3, 6, or 10 microg per kilogram)
Number of subjects: 45
Study 17050891 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 531 (1 or 3 microg per kilogram)
Number of subjects: 45
Study 17050891 — intervention group
Group type: COMPARATOR
Intervention: AMG 531 (1 microg per kilogram)
Number of subjects: 45
Study 17050891 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 531 (3 microg per kilogram)
Number of subjects: 45
Study 17050891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 13678479 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin ER 500 mg once daily for 5 days
Number of subjects: 539
Study 13678479 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V 500 mg three times daily for 10 days
Number of subjects: 539
Study 10490554 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic treatment with alteplase
Number of subjects: 224
Study 10490554 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase followed by transfer to the PTCA centre and rescue PTCA if indicated
Number of subjects: 224
Study 10490554 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer for primary PTCA
Number of subjects: 224
Study 8739554 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg daily for 16 days)
Number of subjects: 0
Study 8739554 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg, SC)
Number of subjects: 0
Study 8739554 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 0
Study 2009163 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight wheelchair
Number of subjects: 26
Study 2009163 — intervention group
Group type: COMPARATOR
Intervention: Standard wheelchair
Number of subjects: 26
Study 6765541 — intervention group
Group type: EXPERIMENTAL
Intervention: 15:85% human insulin mixture
Number of subjects: 9
Study 6765541 — intervention group
Group type: COMPARATOR
Intervention: 10:90% human insulin mixture
Number of subjects: 9
Study 6765541 — intervention group
Group type: COMPARATOR
Intervention: 20:80% human insulin mixture
Number of subjects: 9
Study 6765541 — intervention group
Group type: EXPERIMENTAL
Intervention: 15:85% and 20:80% human insulin mixtures
Number of subjects: 9
Study 30188773 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic Latanoprost (GL)
Number of subjects: 6317
Study 27435303 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fish oil (FO) supplementation after the first week of PN
Number of subjects: 52
Study 27435303 — intervention group
Group type: COMPARATOR
Intervention: Vegetal oil (control group)
Number of subjects: 52
Study 26148915 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate red wine drinkers (≥ 1 drink/d)
Number of subjects: 5801
Study 26148915 — intervention group
Group type: COMPARATOR
Intervention: Non-drinkers
Number of subjects: 5801
Study 24766295 — intervention group
Group type: EXPERIMENTAL
Intervention: Rikkunshito (2.5 g three times a day for 8 weeks)
Number of subjects: 247
Study 24766295 — intervention group
Group type: EXPERIMENTAL
Intervention: Rikkunshito
Number of subjects: 247
Study 24766295 — intervention group
Group type: EXPERIMENTAL
Intervention: Rikkunshito (among H. pylori-infected participants)
Number of subjects: 247
Study 24766295 — intervention group
Group type: EXPERIMENTAL
Intervention: Rikkunshito (among H. pylori-uninfected participants)
Number of subjects: 247
Study 24766295 — intervention group
Group type: EXPERIMENTAL
Intervention: Rikkunshito (among H. pylori-positive individuals)
Number of subjects: 247
Study 24766295 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three times a day for 8 weeks)
Number of subjects: 247
Study 22926604 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (50 to 300 mg/d, mean = 132.2 mg)
Number of subjects: 51
Study 22926604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 19004846 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib
Number of subjects: 0
Study 19004846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 0
Study 17691579 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at bilateral cervical Jiaji (EX-B 2)
Number of subjects: 60
Study 17691579 — intervention group
Group type: COMPARATOR
Intervention: Control acupuncture points: Fengchi (GB 20), Taichong (LR 3), Quchi (LI 11), Zusanli (ST 36), Sanyinjiao (SP 9)
Number of subjects: 60
Study 15050907 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (40 mg daily in 3-month blocks)
Number of subjects: 72
Study 15050907 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate (60 mg every 3 months as a single infusion)
Number of subjects: 72
Study 15050907 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (40 mg daily) in previously untreated patients
Number of subjects: 72
Study 15050907 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate in previously untreated patients
Number of subjects: 72
Study 15050907 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (40 mg daily) in previously treated patients
Number of subjects: 72
Study 15050907 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate in previously treated patients
Number of subjects: 72
Study 15050907 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate after crossover from pamidronate
Number of subjects: 72
Study 11467466 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study 11467466 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 10190530 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 56
Study 10190530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 7761376 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination levorin + furadonin + nitroxoline
Number of subjects: 0
Study 7761376 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 2102704 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-carbomethoxythiazolidine
Number of subjects: 20
Study 2102704 — intervention group
Group type: COMPARATOR
Intervention: N-acetyl-L-cysteine
Number of subjects: 20
Study 7405545 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective induction with oxytocin
Number of subjects: 81
Study 7405545 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous delivery
Number of subjects: 81
Study 31219919 — intervention group
Group type: EXPERIMENTAL
Intervention: Reclassification of ASA-PS using pediatric-specific definitions
Number of subjects: 120
Study 28738708 — intervention group
Group type: EXPERIMENTAL
Intervention: HBB 20 mg
Number of subjects: 120
Study 28738708 — intervention group
Group type: EXPERIMENTAL
Intervention: HBB 40 mg
Number of subjects: 120
Study 28738708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 26740049 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass graft surgery (OPCAB)
Number of subjects: 206
Study 26740049 — intervention group
Group type: COMPARATOR
Intervention: On-pump coronary artery bypass graft surgery
Number of subjects: 206
Study 24918911 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletonized radial artery (20 patients)
Number of subjects: 40
Study 24918911 — intervention group
Group type: COMPARATOR
Intervention: Radial artery with adjacent tissues (20 patients)
Number of subjects: 40
Study 23116377 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's Psychosocial Rehabilitation Treatment Adherence Measure (CTAM) for CPSR
Number of subjects: 106
Study 23116377 — intervention group
Group type: COMPARATOR
Intervention: Children's Psychosocial Rehabilitation Treatment Adherence Measure (CTAM) for psychotherapy
Number of subjects: 106
Study 20116388 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual learning through computer displays depicting structure-from-motion (SFM) over three sessions a day for three consecutive days, each session comprising 48 trials.
Number of subjects: 16
Study 20116388 — intervention group
Group type: COMPARATOR
Intervention: Control group (moderate AD) with no improvement in performance.
Number of subjects: 16
Study 18705532 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose amlodipine/benazepril (2.5/5 mg/day titrated to 5/10 mg/day)
Number of subjects: 111
Study 18705532 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine monotherapy (5 mg/day titrated to 10 mg/day)
Number of subjects: 111
Study 18705532 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose amlodipine/benazepril
Number of subjects: 111
Study 18705532 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine monotherapy
Number of subjects: 111
Study 15898129 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen total fundoplication
Number of subjects: 163
Study 15898129 — intervention group
Group type: COMPARATOR
Intervention: Anterior partial fundoplication
Number of subjects: 163
Study 14564289 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-mm tub preparation design
Number of subjects: 80
Study 14564289 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-mm tub preparation design
Number of subjects: 80
Study 14564289 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-mm box preparation design
Number of subjects: 80
Study 14564289 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-mm box preparation design
Number of subjects: 80
Study 14564289 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-mm pontic distance
Number of subjects: 80
Study 14564289 — intervention group
Group type: EXPERIMENTAL
Intervention: Box-shaped tooth preparation
Number of subjects: 80
Study 10791875 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoside analog therapies
Number of subjects: 0
Study 8851904 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant work rate tests at 40, 80, 120, 160, and 200 W
Number of subjects: 12
Study 8851904 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression analysis of VCO2 as a function of VO2
Number of subjects: 12
Study 8851904 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison with ramp protocol
Number of subjects: 12
Study 8851904 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body R at individual work rates
Number of subjects: 12
Study 1363481 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 362
Study 1363481 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 362
Study 1363481 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 362
Study 1363481 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 362
Study 1363481 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 362
Study 1363481 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (increased dose from 240 to 600 mg)
Number of subjects: 362
Study 6383687 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin, 2 gm/day
Number of subjects: 20
Study 6383687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2879444 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (50.0 ± 5.2 mg per day) + Atenolol (89.5 ± 25.7 mg per day)
Number of subjects: 24
Study 2879444 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (460 ± 20 mg per day) + Enalapril (29.5 ± 5.0 mg per day)
Number of subjects: 24
Study 2879444 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (50.0 ± 5.2 mg per day)
Number of subjects: 24
Study 2879444 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (460 ± 20 mg per day)
Number of subjects: 24
Study 30317101 — intervention group
Group type: EXPERIMENTAL
Intervention: O3PUFAs
Number of subjects: 50
Study 30317101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 26314941 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 401
Study 25089359 — intervention group
Group type: EXPERIMENTAL
Intervention: ACN-rich beverage (juice with 983.7 mg/l ACN)
Number of subjects: 30
Study 25089359 — intervention group
Group type: EXPERIMENTAL
Intervention: ACN-rich beverage (smoothie with 840.9 mg/l ACN)
Number of subjects: 30
Study 25089359 — intervention group
Group type: COMPARATOR
Intervention: Placebo juice
Number of subjects: 30
Study 25089359 — intervention group
Group type: EXPERIMENTAL
Intervention: ACN-rich beverage (juice and smoothie)
Number of subjects: 30
Study 23588448 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (G2)
Number of subjects: 90
Study 23588448 — intervention group
Group type: COMPARATOR
Intervention: Control group (G1)
Number of subjects: 90
Study 20156395 — intervention group
Group type: EXPERIMENTAL
Intervention: High identifiers expressing descriptively deviant opinions
Number of subjects: 0
Study 20156395 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-level self-definition as a moderator
Number of subjects: 0
Study 20156395 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-level self-investment as a moderator
Number of subjects: 0
Study 20156395 — intervention group
Group type: EXPERIMENTAL
Intervention: Majority group members violating group norms
Number of subjects: 0
Study 18717508 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone immediate-release (IR)
Number of subjects: 0
Study 18717508 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone extended-release (ER)
Number of subjects: 0
Study 18717508 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated doses of oxymorphone ER
Number of subjects: 0
Study 16365493 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered prilocaine (10 ml of prilocaine hydrochloride 2% buffered with 1 ml of sodium bicarbonate 8.4%)
Number of subjects: 40
Study 16365493 — intervention group
Group type: COMPARATOR
Intervention: Plain prilocaine (10 ml of plain prilocaine hydrochloride 2% solution)
Number of subjects: 40
Study 14644397 — intervention group
Group type: EXPERIMENTAL
Intervention: Avasimibe 750 mg QD
Number of subjects: 27
Study 14644397 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 80 mg QD
Number of subjects: 27
Study 14644397 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of atorvastatin 80 mg QD and avasimibe 750 mg QD
Number of subjects: 27
Study 11021899 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. for 7 days (first phase)
Number of subjects: 362
Study 11021899 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg o.m. for 2 weeks (second phase)
Number of subjects: 362
Study 11021899 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks (second phase)
Number of subjects: 362
Study 8626843 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone transdermal system applied to the back for 24 hours
Number of subjects: 34
Study 8626843 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone transdermal system applied to various sites (abdomen, back, chest, shin, thigh, upper arm) for 24 hours
Number of subjects: 34
Study 1576117 — intervention group
Group type: EXPERIMENTAL
Intervention: D,L‐α‐tocopherol (vitamin E) 1,000 IU/day for 7 days
Number of subjects: 52
Study 1576117 — intervention group
Group type: COMPARATOR
Intervention: β‐carotene supplementation in smokers (n=23)
Number of subjects: 52
Study 1576117 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n=23)
Number of subjects: 52
Study 6374766 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocervical prostaglandin E2 gel (0.5 mg in 2.5 ml)
Number of subjects: 121
Study 6374766 — intervention group
Group type: COMPARATOR
Intervention: Vaginal PGE2 tablet (2.0 mg)
Number of subjects: 121
Study 6374766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 6374766 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocervical prostaglandin E2 gel (0.5 mg) in women with Bishop score 0-2
Number of subjects: 121
Study 6374766 — intervention group
Group type: COMPARATOR
Intervention: Vaginal PGE2 tablet (2.0 mg) in women with Bishop score 0-2
Number of subjects: 121
Study 6374766 — intervention group
Group type: COMPARATOR
Intervention: Placebo in women with Bishop score 0-2
Number of subjects: 121
Study 31662396 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring using Sense4Baby CTG devices, Microlife BP monitor, daily telephone calls with an obstetric healthcare professional, and weekly hospital visits.
Number of subjects: 416
Study 31662396 — intervention group
Group type: COMPARATOR
Intervention: Traditional hospitalisation.
Number of subjects: 416
Study 31662396 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 416
Study 31662396 — intervention group
Group type: COMPARATOR
Intervention: Traditional hospitalisation
Number of subjects: 416
Study 29370217 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric atmosphere (6380 ft)
Number of subjects: 16
Study 29370217 — intervention group
Group type: EXPERIMENTAL
Intervention: Background noise (white noise at 70 dB)
Number of subjects: 16
Study 29370217 — intervention group
Group type: COMPARATOR
Intervention: Normal conditions (no hypobaric or noise)
Number of subjects: 16
Study 27519183 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E + placebo
Number of subjects: 35533
Study 27519183 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium + placebo
Number of subjects: 35533
Study 27519183 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E + selenium
Number of subjects: 35533
Study 27519183 — intervention group
Group type: COMPARATOR
Intervention: Placebo + placebo
Number of subjects: 35533
Study 24512866 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation Intentions (II) technique with a leaflet attached to the test kit containing an 'if-then' condition and planning instructions.
Number of subjects: 2200
Study 24512866 — intervention group
Group type: COMPARATOR
Intervention: Standard care group (Control)
Number of subjects: 2200
Study 22834725 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic or psychoanalytically oriented treatments (PAT), up to 80 sessions in the first year, potentially extended to 240-300 sessions over two to three years.
Number of subjects: 240
Study 22834725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT), up to 60 sessions in the first year, potentially extended to 80 sessions focusing on maintenance and relapse prevention.
Number of subjects: 240
Study 20713651 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat high-carbohydrate (LFHC) diet
Number of subjects: 63
Study 20713651 — intervention group
Group type: COMPARATOR
Intervention: High-fat low-carbohydrate (HFLC) diet
Number of subjects: 63
Study 17545883 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC+ (three sets of six reps at 40% 1RM concentric and 100% 1RM eccentric)
Number of subjects: 22